These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601 [No Abstract] [Full Text] [Related]
24. [Endogenous anticoagulant therapy for sepsis. Success and failure]. Wiedermann CJ Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117 [TBL] [Abstract][Full Text] [Related]
25. [Treatment of severe sepsis and multiple organ failure with activated protein C]. Strøm JJ Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233 [No Abstract] [Full Text] [Related]
26. [Anti-inflammatory treatment in sepsis]. Bloos F; Reinhart K Chirurg; 2002 Nov; 73(11):1087-92. PubMed ID: 12430058 [TBL] [Abstract][Full Text] [Related]
27. Drotrecogin alfa: a role in emergency department treatment of severe sepsis? McLeay AM Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720 [TBL] [Abstract][Full Text] [Related]
28. Kigris. FDA approves first biologic for sepsis. Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924158 [No Abstract] [Full Text] [Related]
30. [Activated protein C--recent addition to therapy of sepsis]. Gårdlund B; Sjölin J Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375 [TBL] [Abstract][Full Text] [Related]
31. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]. Heslet L; Nielsen JD; Schierbeck J; Andersen JS Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234 [No Abstract] [Full Text] [Related]
32. [Xigris--activated protein C]. Tønnesen EK Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235 [No Abstract] [Full Text] [Related]
33. Recombinant human activated protein C. Hughes M Int J Antimicrob Agents; 2006 Aug; 28(2):90-4. PubMed ID: 16837170 [TBL] [Abstract][Full Text] [Related]
34. Beyond sepsis: activated protein C and heat stroke. Brueckmann M; Hoffmann U; Borggrefe M Crit Care Med; 2006 Jul; 34(7):2020-1. PubMed ID: 16801873 [No Abstract] [Full Text] [Related]
35. Drotrecogin alfa: too early to give it early. Smith B Emerg Med Australas; 2005 Apr; 17(2):179-80. PubMed ID: 15796737 [No Abstract] [Full Text] [Related]
37. Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion. Riddell C; Blackwood B Nurs Crit Care; 2006; 11(1):7-15. PubMed ID: 16471293 [TBL] [Abstract][Full Text] [Related]
38. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores SM Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544 [TBL] [Abstract][Full Text] [Related]
39. Best evidence in anesthetic practice: prevention: recombinant human activated protein C reduces mortality in severe sepsis. Butler R; Laufer B Can J Anaesth; 2002 Feb; 49(2):207-9. PubMed ID: 11823403 [No Abstract] [Full Text] [Related]
40. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Grinnell BW; Joyce D Crit Care Med; 2001 Jul; 29(7 Suppl):S53-60; discussion S60-1. PubMed ID: 11445735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]